and and for participating for you, call. thanks Thank our interest your in Brian and Kamada in to analysts also today's investors
to during we momentum XXXX, the year guidance. business extremely our pleased achieve with experienced full operational are and We our financial which allowed us throughout strong
top well year. positioned line for we bottom this and are Importantly, further growth
in $XX.X of business XX, ended to a and XX% I of the million, XXXX. financial of XX% $XXX.X an With XX top high-level which during revenues anticipated total results months line increase December for the will the achieved and as XXXX. robust year-over-year EBITDA represented compared full million, of of our bottom year XXXX. growth begin our growth We with review
growth to U.S. We and KEDRAB continue our drivers of the in U.S. on the in increase effectively leverage business, in market CYTOGAM share market. the the significant promotion focusing
ahead, expect through extend momentum XXXX year Looking increased full profitability meaningfully last revenue generated compared and be the we to to to year with as XXXX.
we over such, of $XXX XX%, to line $XXX we ranges potential upside XXXX top guidance guidance said and downside growth The $XX these and previously, represent of have of beyond As million XXXX million. annual revenue risk. adjusted we introducing full limited and double-digit are what foreseeable reiterate XX% to growth in million approximately would significant revenue year of $XX anticipate EBITDA midpoint profitability and XXXX.
To with profitability respectively, million the years and
the year, we XXXX, was our the a to increase strong existing continue for impactful. pursue are like the experienced I'd compelling opportunities, we to the Additionally, ended our We a balance and financial of product with highlight engaged we business sheet. have to KEDRAB, over in year And both $XX million U.S. process demand our the anti-rabies in growth and actively significant in accelerate business immunoglobulin flexibility especially the cash, in.
In throughout development
is market robust studied in extensive and that obtained to the be coverage in Kedrion's by it approval distribution Following extension amendment expect XXXX commercial XXXX in a share has for first KEDRAB activity, human only agreement for U.S. continue immunoglobulin expansion as trend children. the the this in demonstrated well available as our and as being product the and clinically FDA to beyond. differentiated recent growth rabies label by the and driven Kedrion, fully of with substantial we The market
distribution for revenues further growth in million to agreement, XXXX. on doubled Kedrion $XX.X market, distribution more our new approximately sales is which generated Kamada in Based to U.S. XXXX, the compared sales KEDRAB XXXX. in expected In the from than of
Looking ahead amended agreement with KEDRAB, the Kamada. milestone and tremendous extended is distribution a for
Kedrion inception. agreement commercial strategic agreement the this represent Kamada's since with largest fact, In
the the term, reflect which purchase Kedrion in this the potential of Moreover, focus of Kamada continuation sales of business other the value own years agreement explore of Kedrion KEDRAB as X-year growth began this territories our and to We potential allowing growth X forecasted terms and important throughout with beyond effectively by financial term by of $XXX internal to the future this will of within U.S. this expansion effort Specifically, partnership product. on to primarily transplant must the significant maximizes the continues the and U.S. us centers the in medical January, numerous to across our products, distribution approximately continued the promote immunoglobulin market specialized when U.S. Kedrion revised other KEDRAB centers FDA-approved commercialization share first hospitals KEDRAB X-year U.S. million.
The revenues KEDRAB quantities well past believe minimum of
Moving on.
team achieve portfolio U.S. Our steady IgG and healthcare direct in physician other promoting through specialty XXXX our opportunities in to progress practitioners engagement medical at established and continues to meetings.
are our previously, this As year. activity U.S. and and the we in Each made products activities primarily supported promoting we important these VARIZIG, therapies further represent financial of a by in that the XXXX, to field-based hyper-immune contribution specialty time results CYTOGAM this these have our decade being expect over in important products first said impact
Texas immune high-risk retrospective CMV And recipients Southwestern Importantly, transplant the concluded CMV CYTOGAM from patients Torres, Dr. of XXX and antivirals consisting The a of the University by multimodality lung Division patients Chief, evaluating investigator-initiated of in in Fernando real-world antiviral Pulmonary X-year prevention that prophylaxis the with published donor. recipients. XXXX, Critical an Care consisting mismatch proactive use XXXX mismatch lung Medical receiving improve agents at at Clinical October CMV among lung use IDWeek augmentation Dr. high-risk the Center. disease of also for seronegative of the immunoglobulin were seropositive combination were results may high-risk transplant of Massachusetts. and outcomes with presented mismatch in patients CMV of transplant from study of Boston results in along CMV CMV Torres
are of process with these sharing CYTOGAM. and the promoting We of advantages results experts the physicians transplantation in
already known U.S.-based, product. transplantation and Advisory development of year transplantation continues CYTOGAM organ meetings have by future that notified studies were this Board, to year. which already consists solid accepted for of note, during KOLs opportunities was and leaders medical the and in established evaluate this CYTOGAM leading X last to U.S. additional at new conducted related benefit field, important related research X been our the for We presentation Of Scientific possibilities transplantation thought
on. Moving
enrollment the also for recently Phase pivotal than clinical Antitrypsin extension in to deficiency the to ongoing therapy overall which InnovAATe our design clinical FDA future positive also smaller evaluating for from Board ahead of an safety meeting initiated the the primary study program. catalysts, study, continues to endpoint p-value conducted registration, treatment be Data the program in expected and accept expressed its The alpha accepted the open-label significance. in our plan assessment. unblinded for willingness is of positive acceleration a We FDA endorsed FDA X.X reconfirmed further for in the and InnovAATe level for trial Looking Safety may potentially conduct allow The the ongoing which mid-XXXX.
The efficacy Agency meeting of feedback received Alpha-X the with agency. of X Alpha-X inhaled with Monitoring
plan a statistical the a FDA As SAP InnovAATe by revised we result, study study and seek to mid-XXXX. protocol plan, present analysis and for feedback
and FEVX InnovAATe the measured As study our design also by the prior previously acknowledged studies. the improvement Medicine meaningful in function clinically demonstrated reconfirmed European a of Phase overall in reminder, European Agency, ongoing EMA, X/X statistically and the lung
at-home be sales patients EU. product Alpha-X clinical product of market standard transformational and In $X this the the promising to reiterate already to discussions IV innovative also we what better is late-stage the recently compared and ease the of annual partnering in substantial have previously, billion treatment with the expected use Alpha-X treatment a opportunity an of is to leading investigational clinical is present new to a for parallel and in have inhaled as product will achieved, candidates. treatment of to active potential The and U.S. we said progress in care. regulatory it AAT over in life advanced a stage Kamada's related quality continue current To noninvasive that inhaled
plasma We U.S.-based also Plasma, continue to be Kamada collection pleased with our company. progress achieved the with
product acquisition of collection represented plasma collection Houston, XXXX Texas, market and in plasma goal of Our plasma strategic company. the the into fully center specialty Kamada's integrated U.S. our becoming a supported entry
expected plasma the continue this our at completed plasma and Houston, successfully second hyperimmune our collecting located in year. opened construction of is the to center center first expand be collection capacity We to nearly second during half Texas at
This integrated which company. year innovative as ago, will like if quarter notice call webcast, vertically XXXX. currently to new the hopefully a profitable the plasma the our note the of I'll by now results Kamada's fourth over Finally, it transformation launched I logo full Chaime and logo our discussion viewing through a for leading financial new going weeks few detailed now. represent the you you're to turn With specialty for that, would
Chaime, please ahead. go
